Recent developments in liquid chromatography, such as the introduction of ultra-high performance liquid chromatography (UHPLC) instruments and columns with sub-2 μm and solid core particles, make ultra-fast separations possible. Combined with the current trend towards the use of high-resolution mass spectrometry (HRMS) in quantitative applications, this would allow simultaneous high-throughput quantitative bioanalysis and information-rich, qualitative metabolite identification within a single, short analysis, in a so-called Quan/Qual workflow.

The aim of this project, which is a collaboration project of the LACDR and Janssen Pharmaceutica NV, is to develop a generic method for Quan/Qual analysis of small molecule drugs, their metabolites and endogenous metabolites in (pre-)clinical samples. Such a method is of high value in drug development, as it would reduce the need for compound-specific bioanalytical method development, and it can be applied to a variety of studies, including tox-studies and drug metabolism studies. Due to the untargeted approach, the data collected with this method will contain a myriad of information that has the potential to be used not only for the traditional objectives of parent drug pharmacokinetics and metabolite identification, but also for biomarker discovery.

Share on Facebook Share on X Share on LinkedIn Share by WhatsApp Share by Mastodon